江南·体育(JN SPORTS)官方网站,江南体育app下载

|
|
EN

  • 业务咨询

    中国：

    Email: marketing@hangzhouaijunshengwu.com

    业务咨询专线：400-780-8018

    （仅限服务咨询，其他事宜请拨打川沙总部电话）

    川沙总部电话: +86 (21) 5859-1500

    海外：

    +1(626)986-9880(U.S. - West Coast)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com
在线留言×
点击切换
News information
新闻资讯

BioTrinity 2022——共同催化生命科学行业增长！

2022-04-22
|
访问量：

BioTrinity-2022——共同催化生命科学行业增长.jpg

BioTrinity 2022 is only a couple weeks away! Medicilon is excited to attend and exhibit at the conference. Our Vice President and Business Development team will be exhibiting at the conference. We are happy to meet you in person to discuss how our services and capabilities would support your current research needs and expedite your drug discovery and development programs. We look forward to seeing you soon and wish you safe trips!
BioTrinity 2022 集行业之声，让中国医药界感知 BioTrinity 的新讯息。美迪西很高兴能参加此次BioTrinity 。我们欧洲团队将出席此次会议。我们期待与您会面并讨论美迪西的强大服务能力将如何支持您的研发需求，并加快您的药物研发！
Date: April 26-27, 2022
locations: England, United Kingdom

ABOUT BioTrinity 2022何为BioTrinity？

BioTrinity is an established, must-attend London conference, that catalyses growth and supports in-person re-engagement across the life sciences industry. The event is attended by an audience of early stage and emerging life sciences R&D Companies, investors, big pharma, and other valued partners throughout the life sciences ecosystem. The conference features a focused, relevant, and stimulating programme, led by great speakers, who bring their knowledge, expertise, and vision to the fore in exciting, high-quality sessions.
❖ 这是一次生命科学行业的面对面深度会谈。参加此次活动的有早期和新兴生命科学研发公司、投资者、大型制药公司和整个生命科学生态系统中的其他重要合作伙伴。江山代有人才出，由众多的优秀演讲者带来新技术的分享！
❖ 七个核心治疗领域——肿瘤学、中枢神经系统、微生物组、炎症、罕见病、传染病以及人工智能和数据。

Innovative Drug R&D Services创新药研发服务

Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world. We provide one-stop customized R&D solutions ranging from precise drug targeting to IND filing assistance.Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D.
Innovative Drug R&D Services

❖ Antibody-Drug Conjugate(ADC) R&D project

❖ PROTAC Drug Discovery Research Platform

❖ mRNA Vaccine Bioanalysis Platform

❖ Non-clinical Research for Cellular Immunotherapies

美迪西深度整合研发经验，不断攀登研发技术高峰，搭建新药研发一体化创新服务平台：
❖ ADC临床前研发项目
❖ PROTAC 药物发现技术平台
❖ mRNA疫苗生物分析技术平台
❖ 细胞免疫治疗药物平台等
相关新闻
江南·体育(JN SPORTS)官方网站